Modified Kigali combined staging predicts risk of mortality in HIV-infected adults in Lusaka, Zambia

AIDS Research and Human Retroviruses

Volumn 24, Issue 7, 2008, Pages 919-924

  Peters, Philip J ^a,g   Zulu, Isaac ^b   Kancheya, Nzali G ^b   Lakhi, Shabir ^b   Chomba, Elwyn ^b   Vwalika, Cheswa ^c   Kim, Dhong Jin ^d   Brill, Ilene ^d   Meinzen Derr, Jareen ^e   Tichacek, Amanda ^f   Allen, Susan A ^f  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c Zambia Emory HIV Research Project   (Zambia)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY   (United States)

^g Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MARITAL THERAPY; MODIFIED KIGALI COMBINED STAGING SYSTEM; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEROCONVERSION; STAGING; SURVIVAL RATE; ZAMBIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD SEDIMENTATION; BODY MASS INDEX; COHORT STUDIES; DISEASE-FREE SURVIVAL; FAMILY CHARACTERISTICS; FEMALE; HEMATOCRIT; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; MALE; PROBABILITY; RISK FACTORS; SURVIVAL RATE; URBAN POPULATION; ZAMBIA;

EID: 48749119513     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0297     Document Type: Article

References (28)

1. UNAIDS: Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections: Zambia, 2004 Update. Available at http://data.unaids.org/ Publications/Fact-Sheets01/zambia_EN.pdf. Accessed on August 20, 2007.
2. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: A collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000;355:1131-1137.
3. Lyles RH, Munoz A, Yamashita TE, et al.: Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000;181:872-880.
4. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, and Whitworth JA: HIV-1 infection in rural Africa: Is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002;16:597-603.
5. Leroy V: Four year natural history. J Acquir Immune Defic Syndr 1995;9:415-421.
6. Crampin AC: Long-term follow-up of HIV-positive and HIV-negative individuals in rural Malawi. AIDS 2002;16:1545-1550.
7. Lavreys L, Baeten JM, Chohan V, et al.: Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis 2006;42:1333-1339.
8. Whittle H: Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection. AIDS 1992;6:685-689.
9. Kaleebu P, French N, Mahe C, et al.: Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J Infect Dis 2002;185:1244-1250.
10. Malamba SS, Morgan D, Clayton T, Mayanja B, Okongo M, and Whitworth J: The prognostic value of the World Health Organization staging system for HIV infection and disease in rural Uganda. AIDS 1999;13:2555-2562.
11. Teck R, Ascurra O, Gomani P, et al.: WHO clinical staging of HIV infection and disease, tuberculosis and eligibility for antiretroviral treatment: Relationship to CD4 lymphocyte counts. Int J Tuberc Lung Dis 2005;9:258-262.
12. Zachariah R, Teck R, Ascurra O, Humblet P, and Harries AD: Targeting CD4 testing to a clinical subgroup of patients could limit unnecessary CD4 measurements, premature antiretroviral treatment and costs in Thyolo District, Malawi. Trans R Soc Trop Med Hyg 2006;100:24-31.
13. Diomande FV, Bissagnene E, Nkengasong JN, et al.: The most efficient use of resources to identify those in need of antiretroviral treatment in Africa: Empirical data from Cote d'Ivoire's Drug Access Initiative. AIDS 2003;17(Suppl. 3):S87-93.
14. Severe P, Leger P, Charles M, et al.: Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
15. Stringer JS, Zulu I, Levy J, et al.: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: Feasibility and early outcomes. JAMA 2006;296:782-793.
16. Lifson AR, Allen S, Wolf W, et al.: Classification of HIV infection and disease in women from Rwanda. Evaluation of the World Health Organization HIV staging system and recommended modifications. Ann Intern Med 1995;122:262-270.
17. Lau B, Sharrett AR, Kingsley LA, et al.: C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006;166:64-70.
18. Drain PK, Kupka R, Msamanga GI, Urassa W, Mugusi F, and Fawzi WW: C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS 2007;21:2067-2075.
19. McKenna SL, Muyinda GK, Roth D, et al.: Rapid HIV testing and counseling for voluntary testing centers in Africa. AIDS 1997;11(Suppl. 1):S103-110.
20. Fideli US, Allen SA, Musonda R, et al.: Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001;17:901-910.
21. Modjarrad K, Zulu I, Karita E, Kancheya N, Funkhouser E, and Allen S: Predictors of HIV serostatus among HIV discordant couples in Lusaka, Zambia and female antenatal clinic attendants in Kigali, Rwanda. AIDS Res Hum Retroviruses 2005;21:5-12.
22. Paxton H, Pins M, Denton G, McGonigle AD, Meisner PS, and Phair JP: Comparison of CD4 cell count by a simple enzyme-linked immunosorbent assay using the TRAx CD4 test kit and by flow cytometry and hematology. Clin Diagn Lab Immunol 1995;2:104-114.
23. Anastos K, Kalish LA, Hessol N, et al.: The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: Results of the women's interagency HIV study. AIDS 1999;13:1717-1726.
24. World Health Organization: Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance: African region. World Health Organization, Geneva, Switzerland, 2005.
25. Moss AR, Bacchetti P, Osmond D, et al.: Seropositivity for HIV and the development of AIDS or AIDS related condition: Three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) 1988;296:745-750.
26. Lefrere JJ, Salmon D, Doinel C, et al.: Sedimentation rate as a predictive marker in HIV infection. AIDS 1988;2:63-64.
27. Schwartlander B, Bek B, Skarabis H, Koch J, Burkowitz J, and Koch MA: Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group. AIDS 1993;7:813-821.
28. Lindan CP, Allen S, Serufilira A, et al.: Predictors of mortality among HIV-infected women in Kigali, Rwanda. Ann Intern Med 1992;116:320-328.